Copycat 'biosimilars' win fast track, but FDA says this Bay Area company must slow down

Despite a Supreme Court decision shaving six months off the time it would take a maker of a so-called biosimilar to get to market, Coherus BioSciences Inc. lost nearly a quarter of its value Monday as regulators held off on approving its lower-cost biologic copycat version of a blockbuster brand-name drug. Redwood City-based Coherus (NASDAQ: CHRS) had asked the Food and Drug Administration to approve CHS-1701, its version of Amgen Inc.'s Neulasta. But the FDA said Monday that it needed Coherus to…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news